NCPA warns against challenges associated with Comprehensive Addiction and Recovery Act of 2016

ALEXANDRIA, Va. – The National Community Pharmacists Association recently submitted comments to the Centers for Medicare and Medicaid Services regarding the implementation of Sec. 704 (also known as the pharmacy “lock-in” provision) in the Comprehensive Addiction and Recovery Act of 2016, the association announced Tuesday. According to NCPA, at-risk Medicare Part D beneficiaries are the target of this initiative trying to stem the rise of opioid abuse.



“NCPA worked in a bipartisan, bicameral fashion to ensure that the need to address the abuse of opioids among seniors did not create undue hardships in accessing prescription painkillers,” stated Douglas Hoey, CEO NCPA. “However, we do have lingering concerns that we expressed to CMS to ensure the implementation process runs as smoothly as possible.”



NCPA addressed several areas where independent community pharmacies and the patients they serve could be adversely affected without further clarification from CMS:

 

• 
  Besides opioids, NCPA recommends that no other scheduled drugs be considered for the program at its inception. NCPA appreciates that CMS has historically required plans take a step-wise approach to prevent overutilization. In this same manner, NCPA asked that CMS limit the list of frequently abused drugs for lock-in purposes;


• 
  Residents of assisted living facilities and patients under a doctor’s care for treatment of cancer or related conditions should be exempt from the lock-in provision. To require these patients receive pharmacy services from an outside provider is not feasible and leads to disconnects in care; and


• 
  Notices sent to patients placed in the lock-in program by plans/PBMs should make clear the program only applies to opioids, so patients are not confused and believe they have to have all prescriptions filled at the lock-in pharmacy. In addition, patient lock-in status should be shared with current prescribers and pharmacies, including duration of the program and specific medications impacted.